I see the ramp is over and the dump is well underway…
Is that phase II/III trial ever going to start….. |
Does this mention IMM |
https://www.newscientist.com/article/mg26535322-100-inside-the-new-therapies-promising-to-finally-beat-autoimmune-disease/ |
Triple short term low. Will it bounce or drop to new medium term lows??? |
Plenty of space on the market - clients and partners. |
I'm just saying fake virus (flu), fake vaccine, fake lockdowns fake mask mandates. Sheeple who had the vaccine now very sick for multiple reasons. If not now, anytime. |
That’s one of the most ridiculous posts I have ever seen on these boards….ԍ00;😂😂;😂
There is zero chance of Pfizer buying IMM! |
Pfizer might buy IMM. Their vaccine destroys the immune system and this can fix it. It's good business. Hopefully they'll buy it for USD2B |
 I see Cabaletta's CAR-T also making good progress in lupus - IMM + Avion need to get a move on or there'll be nothing left for them.
Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and dermatomyositis without the need for steroids or immunosuppressants, according to a group of analysts.
The updated phase 1/2 data come from the first 10 patients dosed with resecabtagene autoleucel (rese-cel), previously known as CABA-201, which were presented at the American Association for the Advancement of Science annual meeting last week in Boston. The patients are part of Cabaletta’s RESET program across inflammatory muscle condition myositis, systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).
Last month, the biotech shared safety data showing rese-cel was well tolerated among eight patients, with the new update including data on two more patients in SLE/lupus nephritis (LN), plus initial efficacy data.
As of Jan. 8, 2025, 10 patients had been dosed with a one-time infusion of rese-cel and had at least one month of follow-up.
In the SLE trial, three out of four patients in the non-renal cohort achieved remission as of the most recent follow-up visit. The first patient dosed in the LN group achieved a complete renal response (CRR).
All six SLE and LN patients are off all immunosuppressants and steroids as of the data cut-off date.
[...] |
https://youtu.be/lDm5e9fzQB4?si=hV0IiGpQsA4gcxGd |
And….
This has been known for years… |
moron alfred |
All that pumping and they only managed to raise just over £1m! Just goes to show what little interest there is in the company! |
So they released a pump RNS a few weeks ago, to help get a placing away this week.Classic.Lemmings and mushrooms only. |
Yes supernumerary. The stream of positive newsflow back in 2016-2018 carried the shares from around 25p to 180p. That is what holders are expecting. Old lollywally continues to hold the shares he bought at 7p+ a few years ago presumably because he also anticipates a positive stream of newsflow. Or perhaps he doesn't? All we know about lollywally is that when the shares fall he likes to bash other people, and when the shares rise he gives himself a pat on the back. He is little more than a pointless commentator, I'm afraid. |
supernumerary - I'm assuming your post was sarcastic, seeing as only one of the past six Lanstead deals actually resulted in gains for IMM.
And that was back in 2016 when the share price was riding relatively high in the build up to the first (failed) P3 trial. |
wiggy - you're right - McCarthy is a past master at getting the best out of these Lanstead deals, which requires a constant news flow to keep the share price buoyant. If he can pull the trick off again, there's certainly a potential for trading profits, but I retain doubts about the longer term. |
Nobby - quite :¬) The world isn't standing still - even if they do eventually get through the trial successfully, there'll be an awful lot more competition around, which will be supported by companies with much deeper pockets.
McCarthy's doing a great job keeping this alive, but not so well at advancing the drug. |
There may be interim results, there may be partnership news, there may be upfront payments... there may be all kinds of lovely things over the next couple of years. GLA |
The point being we are unlikely to get the final results from the Avion trial until 2028 now. Yes I know there will be some interim results concerning the dose level along the way but the fund raise today is essentially due to these extended delays |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
